Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

We present a nationwide prospective Swedish registry‐based study of Waldenström macroglobulinaemia (WM), that focuses on incidence and survival in relation to clinical prognostic factors and primary systemic therapies. A total of 1511 patients with WM and lymphoplasmocytic lymphoma (LPL) were regist...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of haematology Ročník 183; číslo 4; s. 564 - 577
Hlavní autoři:	Brandefors, Lena, Melin, Beatrice, Lindh, Jack, Lundqvist, Kristina, Kimby, Eva
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Blackwell Publishing Ltd 01.11.2018
Témata:	Diagnosis Hematology Hemoglobin Immunoglobulin M L-Lactate dehydrogenase Lactic acid ldenstrom macroglobulinaemia survival Lymphoma lymphoproliferative disease Macroglobulinemia Medical prognosis Medical records Monoclonal antibodies Patients prognostic factors Rituximab Survival Targeted cancer therapy therapy Waldenstrom macroglobulinaemia Waldenström macroglobulinaemia Waldenström macroglobulinaemia survival prognostic factors lymphoproliferative disease Waldenström macroglobulinaemia Waldenström macroglobulinaemia survival therapy
ISSN:	0007-1048, 1365-2141, 1365-2141
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!